Wrapping up Q2 earnings, we look at the numbers and key takeaways for the health insurance providers stocks, including Oscar Health (NYSE: OSCR) and its peers.
Upfront premiums collected by health insurers lead to reliable revenue, but profitability ultimately depends on accurate risk assessments and the ability to control medical costs. Health insurers are also highly sensitive to regulatory changes and economic conditions such as unemployment. Going forward, the industry faces tailwinds from an aging population, increasing demand for personalized healthcare services, and advancements in data analytics to improve cost management. However, continued regulatory scrutiny on pricing practices, the potential for government-led reforms such as expanded public healthcare options, and inflation in medical costs could add volatility to margins. One big debate among investors is the long-term impact of AI and whether it will help underwriting, fraud detection, and claims processing or whether it may wade into ethical grey areas like reinforcing biases and widening disparities in medical care.
The 12 health insurance providers stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 2.8% while next quarter’s revenue guidance was 1.7% below.
While some health insurance providers stocks have fared somewhat better than others, they have collectively declined. On average, share prices are down 4.7% since the latest earnings results.
Oscar Health (NYSE: OSCR)
Founded in 2012 to simplify the notoriously complex American healthcare system, Oscar Health (NYSE: OSCR) is a technology-focused health insurance company that offers individual and small group health plans through its cloud-native platform.
Oscar Health reported revenues of $4.88 billion, up 70.4% year on year. This print exceeded analysts’ expectations by 2.9%. Overall, it was an exceptional quarter for the company with a beat of analysts’ EPS estimates.
Oscar Health pulled off the fastest revenue growth of the whole group. Investor expectations, however, were likely higher than Wall Street’s published projections, leaving some wishing for even better results (analysts’ consensus estimates are those published by big banks and advisory firms, not the investors who make buy and sell decisions). The stock is down 8.1% since reporting and currently trades at $27.66.
Best Q2: CVS Health (NYSE: CVS)
With over 9,000 retail pharmacy locations serving as neighborhood health destinations across America, CVS Health (NYSE: CVS) operates retail pharmacies, provides pharmacy benefit management services, and offers health insurance through its Aetna subsidiary.
CVS Health reported revenues of $106.1 billion, up 7.3% year on year, outperforming analysts’ expectations by 6.7%. The business had an incredible quarter with a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 8.4% since reporting. It currently trades at $95.66.
Is now the time to buy CVS Health? Access our full analysis of the earnings results here, it’s free.
Weakest Q2: Progyny (NASDAQ: PGNY)
Pioneering a data-driven approach to family building that has achieved an industry-leading patient satisfaction score of +80, Progyny (NASDAQ: PGNY) provides comprehensive fertility and family building benefits solutions to employers, helping employees access quality fertility treatments and support services.
Progyny reported revenues of $350.5 million, up 5.3% year on year, exceeding analysts’ expectations by 0.6%. Still, it was a slower quarter as it posted EBITDA guidance for next quarter missing analysts’ expectations significantly and full-year revenue guidance slightly missing analysts’ expectations.
Progyny delivered the weakest guidance update in the group. As expected, the stock is down 7.8% since the results and currently trades at $27.87.
Read our full analysis of Progyny’s results here.
Humana (NYSE: HUM)
With over 80% of its revenue derived from federal government contracts, Humana (NYSE: HUM) provides health insurance plans and healthcare services to approximately 17 million members, with a strong focus on Medicare Advantage plans for seniors.
Humana reported revenues of $40.87 billion, up 26.2% year on year. This number surpassed analysts’ expectations by 0.6%. It was a satisfactory quarter as it also logged a beat of analysts’ EPS estimates.
The company added 200,800 customers to reach a total of 17.91 million. The stock is flat since reporting and currently trades at $390.00.
Read our full, actionable report on Humana here, it’s free.
Clover Health (NASDAQ: CLOV)
Founded in 2014 to improve healthcare for America's seniors through technology, Clover Health (NASDAQ: CLOV) provides Medicare Advantage plans for seniors with a focus on affordable care and uses its proprietary Clover Assistant software to help physicians manage patient care.
Clover Health reported revenues of $743.2 million, up 55.6% year on year. This print beat analysts’ expectations by 2%. It was an exceptional quarter as it also put up a beat of analysts’ EPS estimates and full-year EBITDA guidance exceeding analysts’ expectations.
The company added 1,536 customers to reach a total of 157,309. The stock is up 9.9% since reporting and currently trades at $4.55.
Read our full, actionable report on Clover Health here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our 9 Best Market-Beating Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
